Cytokinetics, Incorporated (NASDAQ:CYTK) Director John T. Henderson sold 858 shares of Cytokinetics stock in a transaction on Thursday, December 31st. The shares were sold at an average price of $20.31, for a total value of $17,425.98. Following the transaction, the director now owns 1,757 shares in the company, valued at $35,684.67. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Shares of CYTK opened at $20.78 on Friday. The company has a market capitalization of $1.47 billion, a PE ratio of -10.88 and a beta of 1.43. The company has a debt-to-equity ratio of 0.90, a quick ratio of 15.17 and a current ratio of 15.18. The company’s 50 day moving average price is $18.44 and its 200 day moving average price is $21.00. Cytokinetics, Incorporated has a 52 week low of $8.00 and a 52 week high of $30.14.
Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Wednesday, November 4th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.54. Cytokinetics had a negative net margin of 209.88% and a negative return on equity of 3,065.14%. The company had revenue of $41.69 million during the quarter, compared to analyst estimates of $3.80 million. On average, equities analysts forecast that Cytokinetics, Incorporated will post -1.74 earnings per share for the current fiscal year.
Several research analysts recently weighed in on CYTK shares. Raymond James reaffirmed a “buy” rating on shares of Cytokinetics in a research note on Tuesday, November 24th. Morgan Stanley raised their price objective on Cytokinetics from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 16th. The Goldman Sachs Group initiated coverage on Cytokinetics in a research report on Wednesday, October 28th. They set a “neutral” rating and a $16.00 target price on the stock. HC Wainwright dropped their price target on Cytokinetics from $43.00 to $22.00 and set a “buy” rating on the stock in a research note on Monday, November 23rd. Finally, Zacks Investment Research upgraded Cytokinetics from a “sell” rating to a “hold” rating in a report on Monday, November 9th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $30.30.
Cytokinetics Company Profile
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.